Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine. https://lnkd.in/gkJ4d-Tn
关于我们
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company's Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
- 网站
-
https://www.everestmedicines.com/
Everest Medicines的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- New York，NY
- 类型
- 私人持股
地点
-
主要
获取路线
450 Lexington Ave
39B
US，NY，New York，10017
Everest Medicines员工
动态
-
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs. https://lnkd.in/ewxvgCxj
-
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025. https://lnkd.in/gKqMFFmi
-
Honored to be featured in @CBC Group's "Dare to Lead" video! Since our inception in 2017, we've embraced challenges, made bold decisions, and driven meaningful change—all in our vision #BetterMedicinesBetterLife.
At CBC Group, making difficult but right decisions is in our DNA and has shaped our vision of "Better Healthcare for All”. With our unique “Investor-Operator” approach, we partner with our portfolio companies to drive innovation and long-term impact. As we usher in the Lunar New Year, we’re excited to share a moment of inspiration and celebration: "Dare to Lead," a video introducing our portfolio company, @Everest Medicines' extraordinary growth journey since its inception in 2017. From overcoming challenges to making bold decisions, to pioneering meaningful change while creating lasting value, it’s a story of courage, vision, and determination to shape Better Healthcare for All. A heartfelt thank you to all talented colleagues whose dedication made this journey possible! #VaueCreation #InvestorOperator #Courage #BetterHealthcareforAll
-
Everest Medicines Announces the First Prescription of VELSIPITY? in the Greater Bay Area, Officially Benefiting Mainland China Patients. https://lnkd.in/gUT2rr5i
-
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY? by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis. https://lnkd.in/gEA-bt87
-
Everest Medicines Announces the First Prescription of VELSIPITY? Issued in Macau, Officially Beginning to Benefit Asian Patients. https://lnkd.in/g2ec-DJg
-
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy. https://lnkd.in/gyK73tZM
-
Everest Medicines Announces Acceptance of VELSIPITY? New Drug Application in Hong Kong. https://lnkd.in/ejaecbvv
-
Everest Medicines Announces NEFECON?, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List. https://lnkd.in/g_x_Qy3B